Hologic, Inc. $HOLX Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 25.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,141,736 shares of the medical equipment provider’s stock after acquiring an additional 439,916 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Hologic were worth $143,582,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of HOLX. Invesco Ltd. increased its holdings in shares of Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares during the last quarter. United Services Automobile Association purchased a new position in Hologic in the first quarter worth approximately $347,000. K.J. Harrison & Partners Inc acquired a new stake in Hologic during the second quarter worth $1,987,000. Aberdeen Group plc increased its stake in Hologic by 2.8% during the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock worth $15,964,000 after acquiring an additional 6,589 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Hologic by 7.2% in the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider’s stock valued at $168,674,000 after purchasing an additional 174,828 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.0%

NASDAQ HOLX opened at $74.54 on Wednesday. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.34. The firm has a 50 day moving average of $74.52 and a two-hundred day moving average of $69.31. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $16.61 billion, a PE ratio of 30.06, a price-to-earnings-growth ratio of 2.11 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.01 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Mizuho cut Hologic from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd. BNP Paribas cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Friday, November 21st. BNP Paribas Exane cut shares of Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. Finally, Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Five investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $79.29.

Insider Transactions at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.